{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:27:18Z","timestamp":1788532038862,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:p>Bevacizumab has demonstrated efficacy in the treatment of ovarian cancer. However, it can also induce severe toxicity in multiple organ systems, particularly the hematological system. Therefore, this study evaluated hematological toxicities associated with bevacizumab in ovarian cancer, using real-world data. Data were extracted from the FDA adverse event reporting system database, covering the period from Q1 2004 to Q4 2024. Further analyses were conducted on hematological toxicities related to bevacizumab, including their features, time-to-onset, and fatality proportions. Of the 5211 adverse event reports identified, 880 hematotoxicity reports (16.89%) were analyzed. Bevacizumab exhibited positive safety signals for hematological toxicity, as indicated by the reporting odds ratios and the information component analyses. Several adverse events not listed on the bevacizumab drug label were identified, including bone marrow failure, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and atypical hemolytic uremic syndrome. The median time-to-onset of these toxicities was 30 days (interquartile range 10\u2013104), and the fatality rate associated with hematological toxicities related to bevacizumab was 16%. This study indicates that hematological toxicities caused by bevacizumab may emerge early and can have catastrophic consequences. Therefore, early detection and appropriate management of these hematological toxicities associated with bevacizumab are essential.<\/jats:p>","DOI":"10.1097\/md.0000000000048722","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:01:40Z","timestamp":1778896900000},"page":"e48722","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Hematological toxicities in bevacizumab associated with ovarian cancer: A pharmacovigilance study using FDA adverse event reporting system database"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6292-1321","authenticated-orcid":false,"given":"Xuan","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Gynecology, Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Su","sequence":"additional","affiliation":[{"name":"Physical Examination Center, Hebei General Hospital, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihui","family":"Cheng","sequence":"additional","affiliation":[{"name":"Ultrasound Department, Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeqing","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Second Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-3114","authenticated-orcid":false,"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Affiliated Hospital of Chengde Medical University, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260904","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1080\/01443615.2022.2036967","article-title":"Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study.","volume":"42","author":"Akilli","year":"2022","journal-title":"J Obstet Gynaecol"},{"key":"R2-20260904","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1136\/ijgc-2024-005611","article-title":"Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study.","volume":"34","author":"Thaker","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"R3-20260904","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.critrevonc.2015.08.017","article-title":"Bevacizumab in ovarian cancer: focus on clinical data and future perspectives.","volume":"97","author":"Colombo","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R4-20260904","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000448942","article-title":"Bevacizumab in ovarian cancer: state of the art and unanswered questions.","volume":"62","author":"Musella","year":"2017","journal-title":"Chemotherapy"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14740338.2024.2390640","article-title":"Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS).","volume":"24","author":"Yang","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"R7-20260904","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.16601","article-title":"Bevacizumab and gastrointestinal perforations: a review from the FDA adverse event reporting system (FAERS) database.","volume":"54","author":"Wichelmann","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-20260904","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.clinthera.2025.04.016","article-title":"Peripheral neuropathy in patients with ovarian cancer administrating poly ADP-ribose polymerase inhibitors: a real-world study based on Bayesian disproportionality analysis of the US food and drug administration adverse event reporting system.","volume":"47","author":"Yang","year":"2025","journal-title":"Clin Ther"},{"key":"R9-20260904","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1186\/s12885-023-11201-w","article-title":"A real-world disproportionality analysis of Rucaparib: post-marketing Pharmacovigilance data.","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"R10-20260904","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1358\/dot.2011.47.9.1673557","article-title":"Bevacizumab and ovarian cancer.","volume":"47","author":"Lai","year":"2011","journal-title":"Drugs Today (Barc)"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2022.06.022","article-title":"Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: the GINECO randomized phase II TAPAZ study.","volume":"166","author":"Joly","year":"2022","journal-title":"Gynecol Oncol"},{"key":"R12-20260904","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2021.01.028","article-title":"The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis.","volume":"161","author":"Liu","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R13-20260904","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/14740338.2023.2248876","article-title":"A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database.","volume":"23","author":"Tang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R14-20260904","doi-asserted-by":"crossref","first-page":"20420986241274909","DOI":"10.1177\/20420986241274909","article-title":"Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA adverse event reporting system database.","volume":"15","author":"Li","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"R15-20260904","doi-asserted-by":"crossref","first-page":"1339505","DOI":"10.3389\/fphar.2024.1339505","article-title":"Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database.","volume":"15","author":"Hu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R16-20260904","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.21037\/tlcr-21-464","article-title":"Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system.","volume":"10","author":"Bai","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"R17-20260904","first-page":"1","article-title":"Real-world data analysis of topotecan in combination with bevacizumab or cycloPhosphamide in the FDA adverse event reporting system (FAERS) database.","author":"Chen","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ijc.34332","article-title":"Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis.","volume":"152","author":"Gu","year":"2023","journal-title":"Int J Cancer"},{"key":"R19-20260904","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1002\/cncr.28283","article-title":"Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.","volume":"119","author":"Barnett","year":"2013","journal-title":"Cancer"},{"key":"R20-20260904","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"R21-20260904","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMc080770","article-title":"VEGF inhibition and renal thrombotic microangiopathy.","volume":"359","author":"Katavetin","year":"2008","journal-title":"N Engl J Med"},{"key":"R22-20260904","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CN110443","article-title":"Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: a case series and systematic review of the literature.","volume":"96","author":"Hilburg","year":"2021","journal-title":"Clin Nephrol"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial.","volume":"174","author":"Gonz\u00e1lez-Mart\u00edn","year":"2022","journal-title":"Eur J Cancer"},{"key":"R24-20260904","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s10147-022-02169-x","article-title":"The roles and limitations of bevacizumab in the treatment of ovarian cancer.","volume":"27","author":"Nakai","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"R25-20260904","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11239-020-02147-y","article-title":"Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization\u2019s database.","volume":"50","author":"Bonaldo","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"R26-20260904","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 Validation Study.","volume":"40","author":"You","year":"2022","journal-title":"J Clin Oncol"},{"key":"R27-20260904","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cam4.3587","article-title":"Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.","volume":"10","author":"Yagi","year":"2021","journal-title":"Cancer Med"},{"key":"R28-20260904","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system.","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:01:49Z","timestamp":1788530509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":28,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048722","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2025-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}